Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Imahashi, Mayumi ^a,b   Izumi, Taisuke ^c,d   Watanabe, Dai ^e   Imamura, Junji ^a   Matsuoka, Kazuhiro ^a   Ode, Hirotaka ^a   Masaoka, Takashi ^a   Sato, Kei ^c   Kaneko, Noriyo ^f   Ichikawa, Seiichi ^f   Koyanagi, Yoshio ^c   Takaori Kondo, Akifumi ^c   Utsumi, Makoto ^a   Yokomaku, Yoshiyuki ^a   Shirasaka, Takuma ^e   Sugiura, Wataru ^a,b   Iwatani, Yasumasa ^a,b   Naoe, Tomoki ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d The Japan Foundation   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL ACTIVITY; APOBEC3B GENE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; GENE; GENE DELETION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; INFECTION SENSITIVITY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; SYPHILIS; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; MIDDLE AGED; MULTICENTER STUDY;

APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CYTIDINE DEAMINASE; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84899797260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092861     Document Type: Article

References (45)

1. Albin JS, Harris RS (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
2. Goila-Gaur R, Strebel K (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51.
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
4. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
5. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096-7108.
6. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, et al. (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83: 494-497.
7. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060. (Pubitemid 37386201)
8. Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, et al. (2012) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol 19: 1005-1010.
9. Li MM, Wu LI, Emerman M (2010) The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol 84: 88-95.
10. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83: 1992-2003.
11. Smith JL, Pathak VK (2010) Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol 84: 12599-12608.
12. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF (2010) A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol 84: 1902-1911.
13. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, et al. (2007) Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 195: 960-964. (Pubitemid 46452100)
14. Chaipan C, Smith JL, Hu WS, Pathak VK (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87: 444-453.
15. Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, et al. (2005) Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 191: 159-163. (Pubitemid 40096372)
16. Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT (2012) APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo. Virology 430: 1-9.
17. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613-9617.
18. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, et al. (2008) Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis 198: 486-492.
19. Vetter ML, Johnson ME, Antons AK, Unutmaz D, D'Aquila RT (2009) Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathog 5: e1000292.
20. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220-11234.
21. Pak V, Heidecker G, Pathak VK, Derse D (2011) The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol 85: 8538-8547.
22. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, et al. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279: 53379-53386. (Pubitemid 40051843)
23. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396. (Pubitemid 39081643)
24. Doehle BP, Schafer A, Cullen BR (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288. (Pubitemid 41169795)
25. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 3: e63.
26. An P, Johnson R, Phair J, Kirk GD, Yu XF, et al. (2009) APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 200: 1054-1058.
27. Itaya S, Nakajima T, Kaur G, Terunuma H, Ohtani H, et al. (2010) No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and Indian populations. J Infect Dis 202: 815-816; author reply 816-817.
28. Bogerd HP, Cullen BR (2008) Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14: 1228-1236. (Pubitemid 351717501)
29. Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80: 5992-6002. (Pubitemid 43849177)
30. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279: 35822-35828. (Pubitemid 39100589)
31. Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol 81: 5000-5013. (Pubitemid 46744412)
32. Wichroski MJ, Robb GB, Rana TM (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2: e41.
33. Stenglein MD, Harris RS (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 281: 16837-16841.
34. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485.
35. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274-4284.
36. Bonvin M, Greeve J (2007) Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J Gen Virol 88: 3270-3274. (Pubitemid 350201836)
37. Abe H, Ochi H, Maekawa T, Hatakeyama T, Tsuge M, et al. (2009) Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. Hepatol Res 39: 1159-1168.
38. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, et al. (2010) Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 88: 72-79.
39. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, et al. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494: 366-370.
40. Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45: 977-983.
41. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, et al. (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis.
42. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, et al. (2012) APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2: 806.
43. Mahieux R, Suspene R, Delebecque F, Henry M, Schwartz O, et al. (2005) Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J Gen Virol 86: 2489-2494. (Pubitemid 41167597)
44. Ooms M, Krikoni A, Kress AK, Simon V, Munk C (2012) APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol 86: 6097-6108.
45. Jha P, Sinha S, Kanchan K, Qidwai T, Narang A, et al. (2012) Deletion of the APOBEC3B gene strongly impacts susceptibility to falciparum malaria. Infect Genet Evol 12: 142-148.